Hemab Therapeutics
COAG
Hemab Therapeutics (COAG) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $64.00 from $55.00 | Aug 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60.00 from $52.00 | Aug 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $52.00 from $40.00 | Jul 13, 2026 |
| Wedbush | Maintained | Outperform | $55.00 from $42.00 | Jul 13, 2026 |
| Jefferies | Maintained | Buy | $47.00 from $39.00 | Jul 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | Jun 26, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $40.00 | Jun 17, 2026 |
| Wedbush | Initiated Coverage | Outperform | $42.00 | May 26, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $50.00 | May 26, 2026 |
| Goldman Sachs | Initiated Coverage | Buy | $36.00 | May 26, 2026 |
| Jefferies | Initiated Coverage | Buy | $39.00 | May 26, 2026 |
Frequently asked questions
What is the latest analyst rating on COAG?
On Aug 12, 2026, Wedbush maintained Hemab Therapeutics at Outperform with a price target of $64.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.